GALANTE EDWARD G
Director · CE, CLH, MPC
As of 2026-09-16, GALANTE EDWARD G has 15 Form 4 transactions on record across 3 companies — 7 in the trailing 12 months.
Everything this person has disclosed to the SEC on Form 4 — across every company they file for — reconstructed from the public record. A filing history, not a tip sheet.
Reconstructed holdings
Reconstructed from this person's own Form 4 filings — the total each filing reported owning afterward, priced at the close on the as-of date shown. A filed position can lag the real one.
Direct and indirect holdings (e.g. through a trust or fund) are tagged separately, as filed.
Trades by company
Filing ledger
| Date | Company | Action | Shares @ price | Value | Ownership Δ | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| 2025-08-14 | CE | Purchase | 2,400 @ $41.27 | $99K | +12.6% of holding | 21,377 | Form 4 |
14 award / exercise / gift records — not counted as purchases
| Date | Company | Action | Shares | Owned after | Filing |
|---|---|---|---|---|---|
| 2026-08-10 | CE | Award / grant | 5 | 6,815 | Form 4 |
| 2026-08-10 | CE | Award / grant | 1,930 | 27,983 | Form 4 |
| 2026-05-20 | CLH | Award / grant | 652 | 25,461 | Form 4 |
| 2026-05-11 | CE | Award / grant | 3 | 6,810 | Form 4 |
| 2026-05-11 | CE | Award / grant | 4,676 | 26,053 | Form 4 |
| 2026-03-10 | CE | Award / grant | 4 | 6,807 | Form 4 |
| 2025-11-12 | CE | Award / grant | 5 | 6,803 | Form 4 |
| 2025-08-11 | CE | Award / grant | 4 | 6,798 | Form 4 |
| 2025-05-21 | CLH | Award / grant | 789 | 24,809 | Form 4 |
| 2025-05-12 | CE | Award / grant | 4 | 6,793 | Form 4 |
| 2025-05-09 | CE | Award / grant | 4,090 | 18,977 | Form 4 |
| 2025-04-01 | MPC | Award / grant | 94 | 23,976 | Form 4 |
| 2025-03-11 | CE | Award / grant | 4 | 6,790 | Form 4 |
| 2025-01-02 | MPC | Award / grant | 294 | 23,766 | Form 4 |
Source: SEC Form 4 filings. Each row links to its original filing.
Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.